Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

J Cancer 2017; 8(1):85-96. doi:10.7150/jca.16792 This issue Cite

Review

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

Cheng Zhang1, 2, 3, Shi-Jie Yang1, 2, 3, Qin Wen1, 2, 3, Jiang F Zhong2, 3, Xue-Lian Chen2, 3, Andres Stucky2, 3, Michael F Press4, Xi Zhang1, 2, 3 ✉

1. Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China.
2. Division of Periodontology, Diagnostic Sciences & Dental Hygiene, and Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, 90033, USA.
3. Norris Cancer Center, University of Southern California, Los Angeles, CA, 90033, USA.
4. Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.

✉ Corresponding author: Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China. E-mail: zhangxxicom (Zhang X). Fax: +86-023-6875-5609.

Citation:
Zhang C, Yang SJ, Wen Q, Zhong JF, Chen XL, Stucky A, Press MF, Zhang X. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J Cancer 2017; 8(1):85-96. doi:10.7150/jca.16792. https://www.jcancer.org/v08p0085.htm
Other styles

File import instruction

Abstract

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression and metastasis, but also has profound effects on therapeutic efficacy. Stromal cells of the TME are increasingly becoming a key consideration in the development of active anticancer therapeutics. However, dispute concerning the role of stromal cells to fight cancer continues because the use of mesenchymal stem/stromal cells (MSCs) as an anticancer agent is dependent on the specific MSCs subtype, in vitro or in vivo conditions, factors secreted by MSCs, types of cancer cell lines and interactions between MSCs, cancer cells and host immune cells. In this review, we mainly focus on the role of human-derived normal MSCs in anticancer therapies. We first discuss the use of different MSCs in the therapies for various cancers. We then focus on their anticancer mechanism and clinical application.

Keywords: Mesenchymal stem/stromal cells, Cancer, Tumor microenvironment.

Citation styles

APA
Zhang, C., Yang, S.J., Wen, Q., Zhong, J.F., Chen, X.L., Stucky, A., Press, M.F., Zhang, X. (2017). Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. Journal of Cancer, 8(1), 85-96. https://doi.org/10.7150/jca.16792.

ACS
Zhang, C.; Yang, S.J.; Wen, Q.; Zhong, J.F.; Chen, X.L.; Stucky, A.; Press, M.F.; Zhang, X. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J. Cancer 2017, 8 (1), 85-96. DOI: 10.7150/jca.16792.

NLM
Zhang C, Yang SJ, Wen Q, Zhong JF, Chen XL, Stucky A, Press MF, Zhang X. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J Cancer 2017; 8(1):85-96. doi:10.7150/jca.16792. https://www.jcancer.org/v08p0085.htm

CSE
Zhang C, Yang SJ, Wen Q, Zhong JF, Chen XL, Stucky A, Press MF, Zhang X. 2017. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J Cancer. 8(1):85-96.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2025 Ivyspring International Publisher. Terms of use